SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB: GNSZ) announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.
